Damascenone inhibits osteoclastogenesis by epigenetically modulating Nrf2-mediated ROS scavenge and counteracts OVX-induced osteoporosis
Phytomedicine · 2024
DOI: 10.1016/j.phymed.2024.156205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Qingliang Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Reactive Oxygen Species, Osteoclasts, Osteoporosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Taishan Scholar Project of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
BACKGROUND: Bone formation and resorption regulate bone homeostasis. Excessive osteoclastogenesis enhances bone resorption and causes osteoporosis. Although medicines targeting osteoclast have been developed, these drugs have several side effects. Natural compounds have advantages in safety and efficiency, making them potential candidates for osteoporosis treatment. PURPOSE: This study aims to elucidate the role of damascenone (Dama) in osteoclastogenesis and osteoporosis. STUDY DESIGN AND METHODS: To demonstrate the effect of Dama on osteoclast differentiation and function, we performed multiple in vitro experiments including TRAP staining, F-actin staining, bone slice resorption assay, real-time PCR, and western bolt. Further, ROS detection, network pharmacology, microscale thermophoresis assay, and ChIP assay were conducted to elucidate the underlying molecular mechanism. Finally, the in vivo effects of Dama were verified using an ovariectomy induced osteoporosis mice model. RESULTS: Dama inhibited RANKL-induced osteoclast differentiation and bone resorptive function in vitro. The expression of osteoclast-related genes and activation of MAPKs and NF-κB signaling in osteoclast were also attenuated by Dama. Meanwhile, Dama reduced intracellular ROS level via up-regulating Nrf2 expression. Network pharmacology demonstrated that HDAC2 is the potential direct target of Dama. Dama inhibited HDAC2 function and increased H3K27ac level of Nrf2, which induced Nrf2 expression and activated ROS scavenging enzymes. Inhibiting NRF2 or activating HDAC2 attenuated the effect of Dama on osteoclastogenesis. Finally, Dama injection suppressed in vivo osteoclastogenesis and ameliorated bone loss induced by OVX. CONCLUSION: Dama attenuates osteoclastogenesis by epigenetically modulating Nrf2 expression and ROS scavenge. This study provides evidence for Dama being a potential treatment for osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, Shandong, China; Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- Department of Orthopedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China.
- Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, Shandong, China; Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Electronic address: newyuliu@163.com.
- Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, Shandong, China. Electronic address: wllspine@163.com.
Förderung
- National Natural Science Foundation of China
- Taishan Scholar Project of Shandong Province
- Natural Science Foundation of Shandong Province
Zitieren
APA
Ma, Q., Xiong, Y., Jie, Z., Li, C., Wang, C., Cai, J., Zhang, Y., Li, J., You, Y., Chang, M., Zhang, D., Qiu, C., Li, Y., Liu, X., & Wang, L. (2024). Damascenone inhibits osteoclastogenesis by epigenetically modulating Nrf2-mediated ROS scavenge and counteracts OVX-induced osteoporosis. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.156205
Vancouver
Ma Q, Xiong Y, Jie Z, Li C, Wang C, Cai J, et al. Damascenone inhibits osteoclastogenesis by epigenetically modulating Nrf2-mediated ROS scavenge and counteracts OVX-induced osteoporosis. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.156205
BibTeX
@article{Ma2024,
author = {Ma, Qingliang and Xiong, Yinuo and Jie, Zhiwei and Li, Changzhen and Wang, Congyu and Cai, Jingwen and Zhang, Yuchen and Li, Jinghang and You, Yunhao and Chang, Mingzheng and Zhang, Dapeng and Qiu, Cheng and Li, Yuhua and Liu, Xinyu and Wang, Lianlei},
title = {Damascenone inhibits osteoclastogenesis by epigenetically modulating Nrf2-mediated ROS scavenge and counteracts OVX-induced osteoporosis},
journal = {Phytomedicine},
year = {2024},
doi = {10.1016/j.phymed.2024.156205}
}
EUVIMED